Efficacy of single-dose cholecalciferol in the blood pressure of patients with type 2 diabetes, hypertension and hypovitaminoses D
de Paula TP, Moreira JSR, Sperb LF, Muller MEP, Steemburgo T, Viana LV
Scientific reports · 8 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Government
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- University or hospital
- Hospital de Clínicas de Porto Alegre
- Government
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
- Nonprofit
- Fundação Instituto de Pesquisas Econômicas
- Grants
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (12/2014); Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (12/2014); Conselho Nacional de Desenvolvimento Científico e Tecnológico (12/2014)
Based on 5 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2020-11-12 · Sci Rep · vol. 10 · issue 1 · p. 19611
- Publisher
- Nature Portfolio
- Cited
- 10 citations · more than 70% of similar papers · 0.6× the field average
- References
- 39 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Blood Pressure and Hypertension Studies · Heart Rate Variability and Autonomic Control · Vitamin D Research Studies
- Keywords
- Cholecalciferol, Vitamin D and neurology, Medicine, Blood pressure, Ambulatory blood pressure, Internal medicine, Placebo, Type 2 diabetes, vitamin D deficiency, Diabetes mellitus, Endocrinology, Diastole, Gastroenterology, Pathology
- MeSH
- humans, hypertension, diabetes mellitus, type 2, vitamin d deficiency, cholecalciferol, blood pressure monitoring, ambulatory, treatment outcome, double-blind method, blood pressure, dietary supplements, aged, middle aged, female, male
6 authors
From BR
- Tatiana Pedroso de Paula · correspondingUniversidade Federal do Rio Grande do Sul; Hospital de Clínicas de Porto Alegre
- Juliano Soares Rabello MoreiraUniversidade Federal do Rio Grande do Sul; Hospital de Clínicas de Porto Alegre
- Luiza Ferreira SperbUniversidade Federal do Rio Grande do Sul; Hospital de Clínicas de Porto Alegre
- Maria Elisa P. MullerUniversidade Federal do Rio Grande do Sul; Hospital de Clínicas de Porto Alegre
- Thaís SteemburgoUniversidade Federal do Rio Grande do Sul
- Luciana Verçoza VianaUniversidade Federal do Rio Grande do Sul; Hospital de Clínicas de Porto Alegre
Abstract
Observational and experimental data reinforce the concept that vitamin D is associated with the pathogenesis of arterial hypertension. We investigated the effect of a single dose of 100,000 IU of cholecalciferol, in office blood pressure (BP), and 24-h ambulatory blood pressure monitoring (ABPM) in patients with type 2 diabetes mellitus (DM), hypertension, and hypovitaminosis D. Forty-three patients were randomized to a placebo or cholecalciferol group. BP was assessed by office measurements and 24-h ABPM, before and after intervention. At week 8, a greater decrease in median ABPM values was observed in cholecalciferol supplementation than in the placebo group for systolic 24-h (- 7.5 vs. - 1; P = 0.02), systolic daytime (- 7 vs. - 1; P = 0.007), systolic nighttime (- 7.0 vs. 3; P = 0.009), diastolic 24-h (- 3.5 vs. - 1; P = 0.037), and daytime DBP (- 5 vs. 0; P = 0.01). Office DBP was also reduced after vitamin D supplementation. A single dose of vitamin D3 improves BP in patients with type 2 diabetes, hypertension, and vitamin D insufficiency, regardless of vitamin D normalization. Vitamin D supplementation could be a valuable tool to treat patients with type 2 DM, hypertension, and hypovitaminosis D.Trial registration: Clinicaltrials.gov NCT02204527.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.